drugset / Trial / NCT04291209
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.
Phase 1/2
Unknown
80 enrolled
Sunnybrook Health Sciences Centre
London Regional Cancer Program, Canada · collabToronto Sunnybrook Regional Cancer Centre · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
Although many intratympanic agents have been attempted, N-Acetylcysteine (NAC) appears to be the most promising and is a powerful, commonly used anti-oxidant. The goal of this prospective phase 2 randomized controlled trial is to determine the optimal dosage and effectiveness of intratympanic NAC injection in reducing hearing loss in head \& neck cancer patients receiving cisplatin chemotherapy with curative intent.
Timeline
- Start
- 2020-02-26
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | N-acetylcysteine | Small molecule | — | Other |